Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Withdrawn 4Unknown 4Recruiting 3Completed 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Thymalfasin × Clear all
NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT02545751 2017-11-28

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Hangzhou Cancer Hospital

Phase 2 Unknown
29 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02787447 2016-11-25

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First People's Hospital of Hangzhou

Phase 2 Unknown
46 enrolled
Thoracic

Adenocarcinoma of Lung

NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡